

# Gemini Stock Analysis Report

---

Based on the analysis of the "Stock Detailed Analysis Report" for Torrent Pharmaceuticals (TORNTPHARM.NS) generated on 2026-01-24, here is my assessment as a Positional Equity Trader.

## Step 1: Audit the Data

- **Data Present:**
  - Daily Price Chart (3-Year) and Candlestick Analysis (Weekly/Daily/15m).
  - Moving Averages (EMA 20, 50, 200).
  - Relative Strength (RS) against Benchmark and Sector.
  - Fundamental Snapshots (Revenue, Net Income, ROE, EPS trends).
  - Technical Indicators: MACD, RSI, Bollinger Bands, Supertrend.
  - Volume Analysis (Distribution days, Exhaustion signals).
  - Analyst Estimates and Price Targets.
- **Data Missing:**
  - Detailed Options Chain/Open Interest data (useful for identifying immediate resistance/support walls, though less critical for pure equity swing trading).
  - Specific news catalysts driving the recent 2.20% drop mentioned in the Trendlyne snapshot.
- **Confidence Level: High.** The report provides a comprehensive technical and fundamental view, allowing for a robust multi-timeframe analysis.

## Step 2: Analyze the Setup

- **Price Structure & Trend:**
  - **Primary Trend: Bullish.** The stock is trading above the 200 EMA (3589), indicating a long-term uptrend.
  - **Intermediate Trend: Weakening/Corrective.** The price (3932) has slipped below the 20 EMA (3949) and is testing the 50 EMA (3857). The "Weakening Leader" classification confirms that while the stock is strong long-term, it is currently lagging the market momentum.
- **Momentum:**
  - **MACD: Bearish.** The MACD line is below the signal line, and the histogram is negative, indicating downward pressure is currently dominant.
  - **RSI: Neutral (50.65).** It has cooled off from overbought levels but hasn't found a hard floor yet.
- **Support & Resistance:**
  - **Critical Support:** The confluence of the 50 EMA (3857) and the Supertrend value (3854). This is the "line in the sand."
  - **Resistance:** The 20 EMA (3949) and the Upper Bollinger Band/Recent Highs (~4118).
- **Volume:**
  - **Bearish** signals are present. Page 18 notes "Buying Exhaustion" and "Distribution Days" in Jan 2026. This suggests institutional profit-taking at higher levels.
- **Valuation & Fundamentals:**
  - While growing, the "No Acceleration" flag and "Overvalued" PE check suggest the stock is priced for perfection. The analyst target of ~4080 implies limited upside (approx. 4%) from current levels unless a major breakout occurs.

## Step 3: Formulate the Recommendation

**Decision: NO.**

**Reasoning:** Entering now is premature. The stock is in a short-term correction within a long-term uptrend. It is

# Gemini Stock Analysis Report

---

currently "catching a falling knife" as it trades below the 20 EMA with bearish momentum (MACD). The reward-to-risk ratio is poor because immediate resistance (3950) is very close, and the stock hasn't successfully confirmed a bounce off the 50 EMA support yet. The upside to the consensus target is below your 5-15% threshold.

**Conditional Plan (Wait for the Setup):** We need to see the stock survive the test of the 50 EMA and reclaim short-term momentum.

- **Condition to Buy:** The price must close **above the 20 EMA** on the daily chart to confirm the correction is over and momentum has returned.
- **Entry Price:** **INR 3,965** (A close above 3950-3960 range).
- **Stop Loss:** **INR 3,840** (Just below the 50 EMA and Supertrend support level of 3854. If this breaks, the intermediate trend is broken).
- **Take Profit:**
  - **Target 1:** **INR 4,120** (Previous High/Upper Bollinger Band - approx 4% gain).
  - **Target 2:** **INR 4,350** (Blue sky breakout extension - approx 10% gain).

*Note: If the stock closes below INR 3,850 before triggering the entry, cancel this setup as it will likely head toward the lower Bollinger Band (~3780) or deeper support.*

## News & Analyst Targets

As a stock research analyst at an investment firm, I have compiled the latest research and developments for **Torrent Pharmaceuticals (TORNTPHARM)** for the week ending **January 25, 2026**.

### 1. Latest News for TORNTPHARM (Week of Jan 19-25, 2026)

The ongoing week has been pivotal for Torrent Pharmaceuticals, headlined by a major acquisition closure and a significant regulatory win.

#### Completion of JB Chemicals Acquisition (Jan 21, 2026):

- Torrent Pharma successfully completed the acquisition of a controlling **46.39% stake** in **JB Chemicals & Pharmaceuticals**.
- The deal, valued at approximately **INR 11,917 crore**, grants Torrent "Promoter" status. This strategic move is expected to significantly strengthen its domestic branded generics portfolio and chronic therapy presence.
- **Management Overhaul:** Following the acquisition, a new leadership structure was announced for JB Chemicals. **Aman Mehta** has been appointed as the new Managing Director, while the previous CEO, **Nikhil Chopra**, will step down from the board but continue as CEO until March 2026.

#### USFDA Clearance for Dahej Facility (Jan 23, 2026):

- The company received a major compliance boost as the **USFDA inspection** at its **Dahej manufacturing facility** concluded with **Zero Observations**.
- This "clean chit" (Voluntary Action Indicated/No Action Indicated status effectively) removes regulatory overhang and validates the facility's adherence to global GMP standards, paving the way for future product approvals.

#### Stock Performance & Fundraising:

# Gemini Stock Analysis Report

- **New 52-Week High:** Driven by the acquisition news, TORNTPHARM stock hit a new **52-week/all-time high** of approximately **INR 4,125** during the week (around Jan 19-20).
- **Debt Fund Raising:** The company is reportedly launching a debt issuance of nearly **INR 12,500 crore** (via bonds/NCDs) to finance the JB Chemicals deal.

## 2. Upgrade/Downgrade from Brokerages

Analyst sentiment remains largely positive, fueled by the synergistic potential of the JB Chemicals deal and the resolution of regulatory inspections.

- **Consensus View:** The analyst community has largely maintained a "**Buy**" or "**Accumulate**" stance. The successful closure of the JB Chemicals deal has solidified confidence in the company's inorganic growth strategy.
- **Recent Shifts:** There were no major *downgrades* reported this week. Most brokerages are currently reviewing the "Combined Entity" financials following the acquisition completion on Jan 21.
- **Previous Key Upgrades:** The stock continues to ride the momentum from late 2025 upgrades, such as **BofA Securities** (upgraded to Buy in Nov 2025) and **JPMorgan** (Overweight), which highlighted the company's superior return ratios and India-business strength.

## 3. Other News Impacting TORNTPHARM

- **Q3 Earnings Season:** While Q3 FY26 results are imminent (expected late January), the market focus this week was dominated by the acquisition news. The "clean" USFDA status acts as a strong precursor to the earnings call, likely mitigating concerns about pricing pressure in the US generics market.
- **Leadership Changes:** The appointment of Aman Mehta to lead the newly acquired JB Chemicals arm signals Torrent's intent to closely integrate and drive operational efficiencies in the new subsidiary immediately.

## 4. Latest Analyst Targets

Below is a summary of the latest available price targets and ratings from major brokerage firms and consensus estimates.

Brokerage / Source	Rating	Target Price (INR)	Date / Status
Trendlyne Consensus	Buy	4,080	Jan 25, 2026
Sharekhan	Buy	4,230	Late 2025 (Maintained)
BofA Securities	Buy	4,000	Nov 2025 (Upgrade)
JPMorgan	Overweight	3,800	Mid-2025 (Maintained)
Motilal Oswal	Neutral	3,770	Late 2025
ICICI Securities	Hold	3,530	Late 2025

**Analyst Note:** The current market price (CMP) is hovering around INR 3,932 - INR 4,020, trading near the consensus target. Analysts are expected to revise targets upward in the coming days to factor in the earnings accretion from the JB Chemicals acquisition.


# Stock Detailed Analysis Report

## **TORNTPHARM.NS**

Current Price: ₹3932.20

Generated: 2026-01-24 18:27

# TORNTPHARM.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

# TORNTPHARM.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	57.0/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.082 [Leader]</b>
3M RS:	<b>1.140 [Leader]</b>
6M RS:	<b>1.132 [Leader]</b>
1Y RS:	<b>1.268 [Strong]</b>
:	

## == TURNAROUND ANALYSIS ==:


Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::


✗ Emerging RS:	<b>Not accelerating</b>
✗ Medium-term Lagging:	<b>Not lagging</b>
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA  
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline






## TORNTPHARM.NS - EMA Crossover Summary

EMA 20:	3949.65
EMA 50:	3857.33
EMA 200:	3589.76
Trend Status:	<b>Strong Uptrend</b>
Golden Cross Date:	2022-07-29 00:00:00+05:30
Golden Cross Price:	1478.41


TORNTPHARM.NS EMA Crossover Analysis



## TORNTPHARM.NS - Bollinger Bands Summary

<b>Current Price:</b>	3932.20
<b>Upper Band:</b>	4118.25
<b>Middle Band (SMA 20):</b>	3950.08
<b>Lower Band:</b>	3781.92
<b>%B:</b>	0.4468
<b>Band Width:</b>	0.0851
<b>Status:</b>	Lower Half
<b>Signal:</b>	None


TORNTPHARM.NS Bollinger Bands (20, 2) Analysis



## TORNTPHARM.NS - Supertrend Summary

Status:	<b>UPTREND (Buy)</b>
Supertrend Value:	3854.01
Signal Identified On:	2025-11-10

Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## TORNTPHARM.NS - MACD Summary

MACD Line:	48.10
Signal Line:	55.66
Histogram:	-7.55
Trend:	<b>Bearish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

TORNTPHARM.NS Price



TORNTPHARM.NS MACD (12, 26, 9)








# TORNTPHARM.NS - Volatility Squeeze Summary

BB Width:	0.0851
ATR:	90.0429
Total Signals:	32
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr
Signal 4:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 3869.80)
Signal 5:	ATR Contraction at 2026-01-06 00:00:00+05:30 (Price: 3936.80)




# TORNTPHARM.NS - Volatility Squeeze Analysis



## TORNTPHARM.NS - RSI-Volume Summary

<b>Current RSI:</b>	50.65
<b>Current Volume:</b>	315842
<b>Volume MA 20:</b>	231351
<b>Bullish Divergences:</b>	1
<b>Bearish Divergences:</b>	1
<b>Bullish Div 1:</b>	Date: 2024-11-19 00:00:00+05:30, Price: 3065.07
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00+05:30, Price: 3328.68

# TORNTPHARM.NS RSI-Volume Divergence Analysis



# TORNTPHARM.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**34 Signals Detected**

:

**2025-11-11 [-]:**

Climax Volume (Churning)

**2025-11-12 [-]:**

Distribution Day

**2025-11-14 [-]:**

Climax Volume (Churning)



**2025-12-11 [+]:**

**Buying Exhaustion (Bearish Div)**

**2026-01-13 [-]:**

Distribution Day

# TORNTPHARM.NS - Volume Analysis




## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	3725.73	3932.2	2025-07-14
1 Day	UPTREND (Buy)	3854.01	3932.2	2025-11-10
15 Min	DOWNTREND (Sell)	3985.32	3932.2	2026-01-23


## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal






## Trendlyne Snapshot - TORNTPHARM\_main



## Trendlyne Snapshot - TORNTPHARM\_forecaster



### Torrent Pharma - TORNTPHARM - stock price prediction, stock forecast, target price, analyst ratings from 27 analysts

Torrent Pharma has a share price target of Rs 4080, revenue growth forecast of 13.3%, and profit growth estimate of 26.4% for FY26, based on top 27 analyst calls.

### Torrent Pharma FORECASTER - Analyst Estimates <sup>①</sup>

[FORECASTER DASHBOARD →](#)

